Announcement • Jul 10
Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary Aldosteronism Pentixapharm Holding AG received notice from the U.S. Food and Drug Administration (FDA) that Fast Track designation has been granted to its development candidate [68Ga]Ga-PentixaFor for the diagnosis of patients with hypertension and underlying primary aldosteronism. In its notification, the FDA determined that Pentixapharm's request meets the criteria for Fast Track designation and that [68Ga]Ga-PentixaFor is accordingly designated as a Fast Track product for the diagnostic subtyping of adult patients with confirmed primary aldosteronism. Fast Track designation is intended to facilitate the development and review of products that address serious conditions and have the potential to fill an unmet medical need. It provides opportunities for more frequent interaction with the FDA during development and may support a more efficient regulatory review process if the relevant criteria are met. The practical benefit of Fast Track designation lies above all in closer and more frequent interaction with the FDA, allowing development and submission questions to be clarified early and the regulatory process to be prepared efficiently. The FDA's specific designation relates to the diagnostic subtyping of adult patients with already confirmed primary aldosteronism, precisely the clinical decision point at which physicians must distinguish between potential surgical treatment and long-term medical therapy. The designation follows Pentixapharm's recent announcement that the Investigational New Drug (IND) application for the U.S. Phase 3 PANDA study of [68Ga]Ga-PentixaFor became effective following the FDA's 30-day review period, with the FDA allowing the study to proceed (“Study May Proceed”). [68Ga]Ga-PentixaFor addresses a central diagnostic bottleneck in primary aldosteronism and hypertension: non-invasive subtyping to guide the treatment decision between surgery and chronic medical therapy. Pentixapharm is preparing to initiate its pivotal Phase 3 PANDA study in the United States. PANDA is designed to evaluate [68Ga]Ga-PentixaFor PET/CT as a non-invasive imaging approach to help identify patients with unilateral primary aldosteronism. This distinction is clinically important because unilateral disease may be treated with surgical removal of the affected adrenal gland in selected patients, while bilateral disease generally requires long-term medical therapy. Primary aldosteronism is one of the most common and substantially underdiagnosed causes of secondary hypertension. The condition occurs when one or both adrenal glands produce too much aldosterone, a hormone that can drive high blood pressure and increase cardiovascular risk. For patients, the key treatment question is not only whether primary aldosteronism is present, but whether excess aldosterone production is coming from one adrenal gland or both. This makes accurate subtyping central to treatment selection and creates a major diagnostic bottleneck in the current care pathway. [68Ga]Ga-PentixaFor is designed to target CXCR4, a biological receptor shown to be strongly expressed in aldosterone-producing adrenal lesions. By visualizing CXCR4 expression with PET/CT, Pentixapharm aims to support a more precise and patient-friendly diagnostic pathway that can help physicians guide patients toward the appropriate treatment option. [68Ga]Ga-PentixaFor is a novel gallium-68-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Clinical experience with [68Ga]Ga-PentixaFor PET/CT in more than 2,000 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo. Pentixapharm is evaluating this established CXCR4 imaging approach in primary aldosteronism, where molecular characterization of adrenal lesions may help address limitations of conventional anatomical imaging. Recent research has shown strong CXCR4 overexpression in aldosterone-producing adrenal tumors, supporting its potential relevance for identifying unilateral disease. Primary aldosteronism (PA) is increasingly recognized as one of the most common and significantly underdiagnosed endocrine disorders worldwide and a leading cause of secondary hypertension. Recent international and Endocrine Society guidelines have expanded recommendations for PA screening, reflecting growing evidence that the disease may affect approximately 5–10% of all patients with hypertension and up to 20–30% of those with treatment-resistant hypertension. Given the high prevalence of hypertension in the United States and globally, even modest improvements in PA detection and subtyping could translate into a meaningfully larger diagnosed and treatment-directed patient population. As awareness, screening, and targeted treatment options continue to advance, the diagnostic landscape for PA is undergoing a fundamental transformation. This shift has the potential to expand the addressable patient population from a highly selected subgroup to millions of patients globally, creating a substantial opportunity for innovative diagnostic approaches aimed at improving disease detection, patient stratification, and treatment selection. Announcement • Jul 03
Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million. Pentixapharm Holding AG has filed a Follow-on Equity Offering in the amount of €20.387392 million.
Security Name: Ordinary Bearer Shares
Security Type: Common Stock
Securities Offered: 11,020,212
Price\Range: €1.85
Transaction Features: Rights Offering New Risk • Jul 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€15m free cash flow). Earnings have declined by 41% per year over the past 5 years. Revenue is less than US$1m (€397k revenue, or US$453k). Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (€58.0m market cap, or US$66.1m). 
